Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News AN2 Therapeutics Inc ANTX

Healthcare
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ANTX)

AN2 Therapeutics to Participate at Upcoming Investor Conferences

Business Wire November 14, 2024

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

Business Wire November 13, 2024

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

Business Wire October 17, 2024

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Business Wire August 28, 2024

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

Business Wire August 16, 2024

AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

Business Wire August 13, 2024

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

Business Wire August 8, 2024

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights

Business Wire May 14, 2024

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

Business Wire March 28, 2024
View More News ››

Opinion & Analysis (NDAQ:ANTX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ANTX)

AN2 Therapeutics Investigated by Block & Leviton For Potenti

NEWS: $ANTX AN2 Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money...
whytestocks - February 12, 2024

Why Is Infectious Disease-Focused AN2 Therapeutics Stock Sin

NEWS: $ANTX Why Is Infectious Disease-Focused AN2 Therapeutics Stock Sinking Today? | BenzingaAN2 Therapeutics Inc@(NASDAQ:ANTX) has...
whytestocks - February 12, 2024

Monday.com Reports Q4 Results, Joins AN2 TherapeuticsAnd Oth

JUST IN: $ANTX Monday.com Reports Q4 Results, Joins AN2 TherapeuticsAnd Other Big Stocks Moving Lower In Monday's Pre-Market Session...
whytestocks - February 12, 2024

AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase

JUST IN: $ANTX AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for...
whytestocks - February 12, 2024
View more Bullboard ››

Southern Silver Exploration Corp.

Southern Silver Exploration Corp.

Southern Silver Exploration Corp is a Canadian company engaged in the acquisition, exploration, and development of natural ...
View More »